Researchers have suggested that uniform evidence standards and reporting requirements could help speed patient access to cell ...

Drug development is an expensive and high-risk process. The median cost per approved drug can reach up to $2.8 billion, ...

A groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...

Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving patient trust and the overall viability of clinical trials.

Clinical trial complexity has significantly increased in the past decade. How can the industry adapt and innovate to remain ...

In this digital era, Vamsi Upputuri, a leading expert in regulatory automation, explores cutting-edge advancements in ...

We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...

Machine learning can help investors dive deeper into trial data to evaluate the true potential of an asset and uncover new ...

Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal ...

Particular barriers to clinical trial and research development in LMIC countries include an awareness of health research and clinical trials, motivation and training of staff to work in clinical ...

New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.